XENE Stock Balance Sheets

Xenon Pharmaceuticals Quarterly Balance Sheets Chart

Quarterly

Annual

Account Receivables

Cash and Cash Eq

Deferred Revenue

Xenon Pharmaceuticals Quarterly Balance Sheets Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30

assets
current assets:
cash and cash equivalents	135,381,000	116,657,000	142,712,000	87,621,000	136,734,000	58,896,000	148,643,000	99,574,000	64,552,000	69,512,000	57,242,000	103,489,000	369,987,000	116,541,000	175,688,000	87,809,000	82,930,000	87,985,000	45,009,000	15,100,000	44,199,000	60,508,000	24,755,000	37,671,000	37,075,000	52,180,000	67,754,000	87,962,000	47,435,000	17,200,000	20,486,000	14,688,000	23,090,000	20,160,000	17,095,000	54,135,000	35,210,000	56,064,000	58,651,000	65,469,000	64,346,000	65,917,000	72,026,000	33,731,000
marketable securities	352,164,000	432,972,000	484,193,000	566,394,000	584,801,000	640,706,000	489,439,000	427,100,000	475,048,000	457,531,000	534,845,000	534,696,000	418,251,000	421,399,000	376,086,000	161,816,000	177,593,000	186,718,000	131,988,000	175,827,000	158,555,000	169,163,000	116,603,000	56,932,000	64,726,000	58,249,000	51,552,000	39,166,000	15,835,000	17,878,000	23,181,000	29,084,000	28,606,000	37,867,000	47,051,000	15,356,000	15,528,000				9,354,000	9,464,000	12,015,000	14,205,000
other receivables	1,097,000
prepaid expenses and other current assets	11,610,000	7,259,000	6,890,000	4,686,000	5,701,000	6,769,000	6,006,000	3,529,000	2,893,000	4,086,000	7,225,000	8,509,000	4,041,000	4,753,000	4,481,000	3,454,000	3,313,000	3,497,000	2,964,000	2,274,000	2,470,000	2,582,000	2,695,000	1,666,000	1,353,000	1,486,000	1,875,000	2,185,000	909,000	1,151,000	716,000	1,086,000	739,000	925,000	1,329,000	1,264,000	1,996,000	1,818,000	1,900,000	371,000	465,000	464,000	686,000	171,000
total current assets	500,252,000																																											48,269,000
marketable securities, long-term	137,297,000	141,498,000	127,496,000	149,317,000	129,062,000	185,836,000	292,792,000	112,407,000	112,592,000	160,265,000	128,682,000	113,989,000
operating lease right-of-use asset	7,290,000	7,617,000	7,939,000	8,258,000	8,573,000	8,884,000	9,193,000	9,497,000	9,799,000	10,097,000	10,406,000	7,559,000	7,730,000	7,900,000	8,056,000	2,967,000	3,086,000	3,206,000	3,326,000	886,000	1,029,000	832,000	933,000	1,036,000	1,135,000	1,233,000
property, plant and equipment	9,205,000	9,696,000	10,278,000	10,162,000	10,138,000	9,393,000	9,653,000	10,236,000	9,563,000	7,975,000	6,500,000	4,575,000	4,536,000	4,336,000	4,466,000	4,261,000	4,326,000	3,691,000	3,554,000	2,954,000	2,347,000	2,155,000	1,660,000	1,212,000	1,316,000	1,198,000	991,000	962,000	1,086,000	1,101,000	1,070,000	1,154,000	1,308,000	1,376,000	1,404,000	1,542,000	1,663,000	1,790,000	1,989,000	2,130,000	2,174,000	2,353,000	2,476,000	1,999,000
deferred tax assets	11,049,000	10,879,000	9,666,000	1,054,000	733,000	400,000	802,000	601,000	445,000	221,000	509,000	514,000	311,000	207,000	465,000	811,000	544,000	514,000	523,000	478,000	290,000	186,000	238,000	178,000	116,000	72,000
prepaid expenses, long-term	9,188,000	8,053,000	7,496,000	7,471,000	7,416,000	7,306,000	7,396,000	7,344,000	7,884,000	7,959,000	7,751,000																				230,000
total assets	674,281,000	743,280,000	798,139,000	835,901,000	884,011,000	919,023,000	964,798,000	671,093,000	684,899,000	719,868,000	754,146,000	775,813,000	807,380,000	558,059,000	572,007,000	264,353,000	274,711,000	290,671,000	189,186,000	199,128,000	210,676,000	237,043,000	147,697,000	98,904,000	105,892,000	114,550,000	122,428,000	130,455,000	65,436,000	37,762,000	46,121,000	46,359,000	54,226,000	60,786,000	67,487,000	73,371,000	55,687,000	61,152,000	63,949,000	69,944,000	76,527,000	79,403,000	87,418,000	54,144,000
liabilities and shareholders’ equity
current liabilities:
accounts payable and accrued liabilities	31,588,000	30,648,000	34,221,000
operating lease liability	1,459,000	1,382,000	1,369,000	1,387,000	1,354,000	1,323,000	1,299,000	1,246,000	1,223,000	1,194,000	488,000				605,000	686,000	759,000	270,000	265,000	596,000	594,000	156,000	168,000	857,000	573,000	722,000
total current liabilities	33,047,000																																											16,343,000
operating lease liability, long-term	7,256,000	7,293,000	7,646,000	8,399,000	8,679,000	9,102,000	9,604,000	9,757,000	10,283,000	10,433,000	9,947,000	7,157,000	7,851,000	8,224,000	7,652,000	2,558,000	2,746,000	2,902,000	3,050,000	188,000	323,000	541,000	743,000
total liabilities	40,303,000	39,323,000	43,236,000	38,094,000	39,964,000	31,325,000	36,877,000	34,501,000	38,442,000	32,924,000	32,649,000	22,694,000																																19,165,000
shareholders’ equity:
common shares, without par value; unlimited shares authorized; issued and outstanding: 76,939,811	1,469,196,000
additional paid-in capital	213,892,000	208,460,000	199,149,000	188,442,000	176,796,000	163,577,000	156,764,000	137,974,000	138,683,000	140,088,000	142,108,000	136,728,000	133,295,000	119,580,000	117,495,000	69,621,000	67,255,000	65,457,000	45,357,000	43,796,000	42,218,000	41,068,000	40,646,000	39,676,000	39,391,000	38,932,000	38,515,000	37,886,000	37,718,000	36,919,000	36,471,000	35,773,000	35,182,000	34,557,000	34,326,000	34,117,000	33,752,000	33,381,000	33,083,000	32,844,000	29,314,000	30,450,000	30,346,000	30,242,000
accumulated deficit	-1,049,223,000	-964,517,000	-899,470,000	-833,785,000	-770,995,000	-713,071,000	-665,140,000	-620,397,000	-571,935,000	-524,474,000	-482,747,000	-445,352,000	-408,202,000	-377,044,000	-357,374,000	-331,810,000	-316,365,000	-294,256,000	-278,492,000	-266,169,000	-257,314,000	-257,139,000	-249,655,000	-238,279,000	-229,408,000	-219,401,000	-207,885,000	-199,327,000	-184,944,000	-177,143,000	-173,388,000	-165,323,000	-157,581,000	-150,201,000	-142,681,000	-136,704,000	-128,972,000	-122,956,000	-119,693,000	-115,754,000	-111,801,000	-107,999,000	-103,734,000	-104,958,000
accumulated other comprehensive income	113,000			1,336,000
total shareholders’ equity	633,978,000	703,957,000
total liabilities and shareholders’ equity	674,281,000	743,280,000	798,139,000	835,901,000	884,011,000	919,023,000	964,798,000	671,093,000	684,899,000	719,868,000	754,146,000	775,813,000	807,380,000	558,059,000	572,007,000	264,353,000	274,711,000	290,671,000	189,186,000	199,128,000	210,676,000	237,043,000	147,697,000	98,904,000	105,892,000	114,550,000	122,428,000	130,455,000	65,436,000	37,762,000	46,121,000	46,359,000	54,226,000	60,786,000	67,487,000	73,371,000	55,687,000	61,152,000	63,949,000	69,944,000	76,527,000	79,403,000
commitments and contingencies
accounts and other receivable		8,649,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 76,586,359		1,460,850,000
accumulated other comprehensive loss		-836,000	-1,612,000		-2,212,000	-1,769,000	-77,000	-2,953,000	-3,299,000	-1,820,000	-3,000,000	-2,955,000	-990,000	-990,000	-990,000	-990,000	-990,000	-990,000	-990,000	-990,000	-990,000	-990,000	-990,000	-990,000	-990,000	-990,000	-990,000	-990,000	-990,000	-990,000	-990,000	-990,000	-990,000	-990,000	-990,000	-990,000	-990,000	-990,000	-990,000	-990,000	-990,000	-990,000
accounts receivable			1,469,000	938,000	853,000	833,000	874,000	805,000	2,123,000	2,222,000	986,000	2,482,000	2,524,000	2,923,000	2,765,000	3,235,000	2,919,000	5,060,000	1,822,000	1,609,000	1,786,000	1,617,000	813,000	209,000	171,000	132,000	256,000	180,000	171,000	432,000	438,000	129,000	198,000	189,000	200,000	595,000	658,000	386,000	315,000	274,000	188,000	1,205,000	215,000	162,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 76,416,086			1,456,836,000
total shareholders' equity			754,903,000	797,807,000	844,047,000	887,698,000	927,921,000	636,592,000	646,457,000	686,944,000	721,497,000	753,119,000
subsequent event
accounts payable and accrued expenses				28,308,000	29,931,000	20,900,000	25,974,000	23,498,000	26,936,000	21,297,000	22,214,000	15,537,000	13,736,000	7,982,000	13,717,000	9,968,000	11,198,000	7,580,000	10,874,000	8,875,000	7,769,000	8,084,000	8,818,000	7,923,000	6,676,000	5,794,000	4,119,000	4,413,000	3,094,000	2,388,000	3,383,000	3,058,000	3,774,000	3,591,000	3,516,000	3,976,000	2,929,000	2,872,000	2,625,000	2,823,000	2,278,000	1,530,000	2,664,000	2,821,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 75,794,409				1,441,814,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 75,667,550					1,440,458,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 75,459,681						1,438,961,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 75,370,977							1,436,374,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 65,002,249								1,121,968,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 63,718,350									1,083,008,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 63,107,020										1,073,150,000
preferred shares, without par value; unlimited shares authorized; issued and outstanding: nil
common shares, without par value; unlimited shares authorized; issued and outstanding: 62,587,701											1,065,136,000
collaboration agreements
common shares, without par value; unlimited shares authorized; issued and outstanding: 62,542,542												1,064,698,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 62,242,883													1,061,690,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 53,059,049														800,307,000
deferred revenue																2,202,000	3,025,000	3,642,000	3,642,000	7,446,000	12,692,000	24,608,000	29,743,000																157,000	2,513,000	5,635,000	8,724,000	11,622,000	13,522,000
preferred shares, without par value; unlimited shares authorized; issued and outstanding: 1,016,000															7,732,000	7,732,000	7,732,000	7,732,000	7,732,000	7,732,000	7,732,000	7,732,000	7,732,000	7,732,000	7,732,000	7,732,000	7,732,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 51,634,752															783,170,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 41,412,875																504,386,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 41,117,568																	499,351,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 40,962,715																		498,334,000
term loan																						15,676,000	4,650,000
deferred revenue, long-term																							709,000
term loan, long-term																							10,889,000	11,786,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 35,012,125																			397,748,000
subsequent events
common shares, without par value; unlimited shares authorized; issued and outstanding: 34,994,946																				397,654,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 34,994,790																					397,652,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 34,956,272																						397,307,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 28,139,228																							294,244,000
operating lease liability, current																								158,000	587,000
term loan, current																								3,616,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 25,868,594																								266,425,000
loan payable, current																									2,067,000
loan payable, long-term																									13,202,000	15,139,000	15,014,000	14,886,000	11,721,000	5,476,000	6,104,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 25,775,056																									266,062,000
current portion of operating lease liability																										582,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 25,771,954																										266,040,000
loan payable, current portion																														1,400,000	700,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 25,750,721																											265,923,000
prepaid expenses, long term																																218,000	285,000	269,000	408,000	479,000	632,000	1,094,000	1,094,000	1,700,000
preferred shares, without par value; unlimited shares authorized; issued and outstanding: 1,568,000																												11,932,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 25,187,441																												261,655,000
preferred shares, without par value; unlimited shares authorized; issued and outstanding: 2,868,000																													21,825,000	21,825,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 17,640,951																													177,012,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 14,171,301																														147,887,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 17,998,420																															173,841,000	173,841,000	173,841,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 17,996,680																																		173,829,000
deferred tenant inducements																																			70,000	86,000	101,000	117,000	133,000	149,000	164,000	180,000	196,000	219,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 17,930,590																																			173,246,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 17,892,933																																				172,886,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 14,415,347																																					148,867,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 14,401,582																																						148,728,000
deferred revenue, less current portion																																											157,000	2,603,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 14,385,336																																							148,634,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 14,344,267																																								148,359,000
fair value of liability classified stock options																																									4,103,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 14,267,174																																									147,824,000
common shares, without par value; unlimited shares authorized; issued and outstanding: 14,222,275																																										147,508,000
deferred financing fees																																												3,876,000
redeemable convertible preferred shares
series a convertible preferred shares, without par value; no shares authorized or outstanding at december 31, 2014; 1,205,761 authorized and 1,151,468 issued and outstanding at december 31, 2013.
series b convertible preferred shares, without par value; no shares authorized or outstanding at december 31, 2014; 1,028,806 authorized and 994,885 issued and outstanding at december 31, 2013.
series e convertible preferred shares, without par value; no shares authorized or outstanding at december 31, 2014; 4,370,920 authorized and 4,322,126 issued and outstanding at december 31, 2013.
shareholders’ equity
common shares, without par value; unlimited shares authorized; 14,181,333 and 1,344,627 issued and outstanding at december 31, 2014 and december 31, 2013, respectively.																																											147,157,000
accumulated comprehensive income																																											-990,000	1,009,000
total liabilities, shareholders’ equity (deficit) and redeemable convertible preferred shares																																											87,418,000
liabilities and shareholders’ deficit
contingencies
redeemable convertible preferred shares:
series a convertible preferred shares, without par value; 1,205,761 authorized and 1,151,468 issued and outstanding at december 31, 2013 and september 30, 2014, respectively																																												2,939,000
series b convertible preferred shares, without par value; 1,028,806 authorized and 994,885 issued and outstanding at december 31, 2013, and september 30, 2014, respectively																																												8,683,000
series e convertible preferred shares, without par value; 4,370,920 authorized and 4,322,126 issued and outstanding at december 31, 2013, and september 30, 2014, respectively																																												90,866,000
total redeemable convertible preferred shares																																												102,488,000
shareholders’ deficit:
common shares, without par value; unlimited shares authorized; 1,344,627 and 1,349,591 issued and outstanding at december 31, 2013 and september 30, 2014, respectively																																												6,198,000
total shareholders’ deficit																																												-67,509,000
total liabilities, shareholders’ deficit and redeemable convertible preferred shares																																												54,144,000
revenue:
collaboration revenue																																												13,192,000
royalties																																												1,000
operating expenses:
research and development																																												3,216,000
general and administrative																																												1,316,000
total operating expenses																																												4,532,000
income from operations																																												8,661,000
other income:
interest income																																												138,000
interest expense
foreign exchange gain																																												392,000
gain on write-off and disposal of assets
net income																																												9,191,000
net income attributable to participating securities																																												5,596,000
net income attributable to common shareholders																																												3,595,000
net income per share
basic																																												2,670
diluted																																												1,690
weighted-average shares outstanding:
effects of dilutive securities:
stock options																																												763,949,000
subscription rights																																												10,400,000

We provide you with 20 years of balance sheets for Xenon Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Xenon Pharmaceuticals. Explore the full financial landscape of Xenon Pharmaceuticals stock with our expertly curated balance sheets.

The information provided in this report about Xenon Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.